BridgeBio Pharma Future Growth

Future criteria checks 2/6

BridgeBio Pharma is forecast to grow earnings and revenue by 48.1% and 39.4% per annum respectively while EPS is expected to grow by 46.9% per annum.

Key information

48.1%

Earnings growth rate

46.9%

EPS growth rate

Biotechs earnings growth	24.7%
Revenue growth rate	39.4%
Future return on equity	n/a
Analyst coverage	Good
Last updated	20 Jun 2024

Recent future growth updates

Recent updates

BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing

Jun 10

BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing

Jul 02

New Forecasts: Here's What Analysts Think The Future Holds For BridgeBio Pharma, Inc. (NASDAQ:BBIO)

May 09

Time To Worry? Analysts Just Downgraded Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Outlook

Feb 28

Analysts Just Made A Major Revision To Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Revenue Forecasts

Jan 09

BridgeBio stock rises as BBP-398, Lumakras combo for lung cancer gets FDA fast track status

Oct 11

BridgeBio, Sentynl's Nulibry for rare disorder in children gets approval in EU

Sep 20

BridgeBio Pharma: Down But Not Out

Aug 31

BridgeBio starts dosing in phase 1 trial of BBP-671 for metabolic disorders

Aug 18

Industry Analysts Just Upgraded Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Revenue Forecasts By 33%

Aug 10

BridgeBio Pharma GAAP EPS of -$0.07 beats by $0.65, revenue of $73.75M beats by $48.75M

Aug 04

BridgeBio, Sentynl's Nulibry get EMA panel nod for approval in EU

Jul 25

Earnings and Revenue Growth Forecasts

NasdaqGS:BBIO - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	554	-306	-392	N/A	9
12/31/2025	248	-528	-501	-521	13
12/31/2024	361	-450	-366	-405	14
3/31/2024	219	-538	-606	-603	N/A
12/31/2023	9	-643	-529	-528	N/A
9/30/2023	9	-613	-498	-496	N/A
6/30/2023	6	-573	-488	-486	N/A
3/31/2023	78	-425	-409	-403	N/A
12/31/2022	78	-481	-426	-419	N/A
9/30/2022	89	-491	-468	-460	N/A
6/30/2022	91	-509	-495	-447	N/A
3/31/2022	71	-596	-555	-508	N/A
12/31/2021	70	-563	-546	-498	N/A
9/30/2021	57	-535	-508	-460	N/A
6/30/2021	63	-495	-477	-470	N/A
3/31/2021	9	-520	-472	-467	N/A
12/31/2020	8	-449	-407	-400	N/A
9/30/2020	22	-402	-387	-380	N/A
6/30/2020	41	-346	-305	-298	N/A
3/31/2020	41	-291	-286	-278	N/A
12/31/2019	41	-261	-256	-254	N/A
9/30/2019	27	-226	-228	-224	N/A
6/30/2019	N/A	-197	-216	-212	N/A
3/31/2019	N/A	-155	-183	-178	N/A
12/31/2018	N/A	-131	-155	-137	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BBIO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BBIO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BBIO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BBIO's revenue (39.4% per year) is forecast to grow faster than the US market (8.6% per year).

High Growth Revenue: BBIO's revenue (39.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if BBIO's Return on Equity is forecast to be high in 3 years time

BridgeBio Pharma Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus revenue estimates increase by 11%

Consensus revenue estimates increase by 138%

Consensus revenue estimates increase by 162%

Consensus revenue estimates increase by 83%

Consensus revenue estimates increase by 44%

Consensus revenue estimates increase by 81%, EPS downgraded

Recent updates

BridgeBio Pharma, Inc. Surpasses Interim Analysis Enrollment Target and Receives U.S. FDA Rare Pediatric Disease Designation for BBP-418, a Potential Treatment for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)

BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing

BridgeBio Pharma, Inc. Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia

BridgeBio Pharma: Upping An Existing Position (Rating Upgrade)

Consensus revenue estimates increase by 11%

CFO & Secretary exercised options and sold US$433k worth of stock

Consensus revenue estimates increase by 138%

Consensus revenue estimates increase by 162%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

BridgeBio Pharma, Inc., Annual General Meeting, Jun 21, 2024

BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement

Consensus revenue estimates increase by 83%

BridgeBio Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $250.00001 million.

Consensus revenue estimates increase by 44%

BridgeBio Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $250.00001 million.

BridgeBio Pharma, Inc. has filed a Follow-on Equity Offering.

Consensus revenue estimates increase by 81%, EPS downgraded

Full year 2023 earnings: EPS and revenues miss analyst expectations

Co-Founder exercised options and sold US$1.8m worth of stock

New major risk - Financial position

BridgeBio Pharma, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy

BridgeBio Pharma, Inc. Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months

Consensus revenue estimates fall by 25%

BridgeBio Pharma: FDA Submission Acromidis And Top Line Results On Deck

BridgeBio Pharma, Inc. Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy in the New England Journal of Medicine

Co-Founder notifies of intention to sell stock

BridgeBio Pharma, Inc. Announces First Child Dosed in PROPEL 3, its Phase 3 Clinical Trial for Infigratinib in Children with Achondroplasia

Now 22% undervalued after recent price drop

Co-Founder notifies of intention to sell stock

BridgeBio Pharma, Inc. Presents Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Consensus EPS estimates fall by 11%, revenue upgraded

Now 22% undervalued after recent price drop

Estimating The Intrinsic Value Of BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates decrease by 13%

BridgeBio Pharma, Inc. Shares Positive Long-Term Data from an Ongoing Phase 2 Study, Which Support the Potential Use of Glycosylated Alpha-dystroglycan (DG) Levels as a Surrogate Endpoint in Limb-Girdle Muscular Dystrophy Type 2I/R9

BridgeBio Pharma, Inc. announced that it expects to receive $250.003806 million in funding from Qatar Investment Authority and other investors

Bridgebio Pharma Announces Positive Feedback from the U.S. Fda and Eu Ema on the Regulatory Path for A Pivotal Phase 3 Trial of Infigratinib in Children with Achondroplasia

BridgeBio Pharma, Inc. Presents Detailed Positive Results from Phase 3 Attribute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) At European Society of Cardiology Congress 2023

Co-Founder notifies of intention to sell stock

New minor risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Bridgebio Pharma Announces Opportunity for Accelerated Approval Pathway in Limb-Girdle Muscular Dystrophy Type 2I (Lgmd2i/R9) Based on Glycosylated Alpha-Dystroglycan (Dg) Levels and Announces First Patient Dosed in Fortify Phase 3 Study

Bridgebio Announces Consistently Positive Results from Phase 3 Attribute-Cm Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy

Price target increased by 20% to US$33.90

BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing

BridgeBio Pharma, Inc. Presents Updated Six Month Results from Its Phase 2 Cohort 5 Trial of Infigratinib in Achondroplasia

CFO & Secretary exercised options and sold US$632k worth of stock

Price target increased by 8.3% to US$28.40

New Forecasts: Here's What Analysts Think The Future Holds For BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Co-Founder notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Co-Founder notifies of intention to sell stock

Consensus revenue estimates increase by 105%

Price target increased by 8.6% to US$23.90

Consensus revenue estimates decrease by 53%, EPS upgraded

Time To Worry? Analysts Just Downgraded Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Outlook

Key Executive notifies of intention to sell stock

Full year 2022 earnings released: US$3.26 loss per share (vs US$3.90 loss in FY 2021)

Analysts Just Made A Major Revision To Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Revenue Forecasts

Co-Founder notifies of intention to sell stock

Bridgebio Pharma, Inc. Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1

Co-Founder exercised options and sold US$654k worth of stock

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

BridgeBio Pharm and ML Bio Solutions Present 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)

BridgeBio Pharma, Inc Presents Updated Positive Data from Its BBP-812 Canavan Disease Gene Therapy Program At the 51st Annual Meeting of the Child Neurology Society

BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 Inhibitor BBP-398 in Combination with Amgen's Lumakras(R) (Sotorasib)

BridgeBio stock rises as BBP-398, Lumakras combo for lung cancer gets FDA fast track status

BridgeBio Pharma, Inc. to Present New Data on its Novel Approaches to RAS-driven Cancers at the Fourth RAS Initiative Symposium